|
House Bill Would Stiffen Penalties for Drug Counterfeiters
|
|
|
| By
Amy Ritter
|
|
|
|
On Nov. 17, 2011, a bill that would increase penalties for those convicted of trafficking in counterfeit drugs was introduced in the House of Representatives. The Counterfeit Drug Penalty Enhancement Act of 2011, cosponsored by four US Senators and two US Representatives.
|
|
|
|
Ben Venue Suspends Manufacturing at Bedford Plant
|
|
|
| By
Erik Greb
|
|
|
|
On Nov. 19, 2011, Ben Venue Laboratories voluntarily and temporarily suspended the manufacture and distribution of products made at its Bedford, Ohio, facility. These products include Doxil (doxorubicin HCl liposome injection), which the company produces for Johnson & Johnson. The company's clients include Pfizer, Hospira, and Teva.
|
|
|
|
SOCMA Raises Concern Over Proposed Legislation for TSCA Reform
|
|
|
| By
Patricia Van Arnum
|
|
|
|
The Society of Chemical Manufacturers and Affiliates issued a statement to the US Senate Committee on Environment and Public Works supporting the evaluation of national chemical-control laws but specifically opposing the Safe Chemicals Act, which was introduced earlier this year by Sen. Frank Lautenberg (D-NJ).
|
|
|
|
European Action Against Antimicrobial Resistance
|
|
|
| By
Stephanie Sutton
|
|
|
|
The European Commission has unveiled a comprehensive action plan against antimicrobial resistance that includes provisions to promote R&D as well as the possibility of establishing fast-track procedures for marketing authorizations.
|
|
|
|
Week of Nov. 21, 2011: Pfizer, MIT Break Ground on New Research Units in Massachusetts; PhRMA Names Richard I. Smith Executive Vice-President of Policy and Research; and More
|
|
|
|
Pfizer, MIT Break Ground on New Research Units in Massachusetts; PhRMA Names Richard I. Smith Executive Vice-President of Policy and Research; and More.
|
|
|
|
Regulatory Roundup: FDA Holds Special Press Briefing Regarding Revocation of Genentech's Avastin
|
|
|
|
FDA Holds Special Press Briefing Regarding Revocation of Genentech's Avastin.
|
|
|
